Deal Tracker · Regions

MENA pharma licensing deals

25 licensing deals in MENA tracked by EPT (2014–2026). Most active: Hikma Pharmaceuticals, Jamjoom Pharma, Avalon Pharma & Bio-Thera Solutions. Latest: Autotelic Bio → Menarini (Licensing, 26 Oct 2026).

25
deals tracked
16
announced in 2026
$353m
disclosed value (2 deals)
100%
licensing, the top deal type
  • EPT has tracked 25 MENA pharma licensing deals (2014–2026), 16 of them announced in 2026.
  • The countries that appear most often are Saudi Arabia (16), China (8), United States (4) & India (3).
  • Values were disclosed for 2 of 25 deals, totalling $353m; the largest is Ocugen → Roots Pharmaceutical ($259m, 14 Oct 2026).
  • The most active companies: Hikma Pharmaceuticals (4), Jamjoom Pharma (4), Avalon Pharma (3) & Bio-Thera Solutions (3).

Most active companies

Hikma Pharmaceuticals (4) · Jamjoom Pharma (4) · Avalon Pharma (3) · Bio-Thera Solutions (3) · SPIMACO (3) · Tabuk Pharmaceuticals (2)

Countries involved

Saudi Arabia (16) · China (8) · United States (4) · India (3) · Iraq (3) · Jordan (3)

Largest disclosed deals

Questions

How many MENA pharma licensing deals has EPT tracked?
25 as of 26 Oct 2026, covering 2014–2026; 16 were announced in 2026. The most recent is Autotelic Bio → Menarini (Licensing, 26 Oct 2026).
Which companies are most active in MENA pharma licensing deals?
Hikma Pharmaceuticals (4 deals), Jamjoom Pharma (4 deals), Avalon Pharma (3 deals), Bio-Thera Solutions (3 deals), SPIMACO (3 deals), Tabuk Pharmaceuticals (2 deals).
What is the largest disclosed MENA pharma licensing deal?
Ocugen → Roots Pharmaceutical: $259m (Licensing, 14 Oct 2026); Daewoong Pharmaceutical → Arcera Life Sciences: $94m (Licensing, 29 Jun 2026). Values are as announced by the parties.
Which countries appear most in MENA pharma licensing deals?
Saudi Arabia (16), China (8), United States (4), India (3), Iraq (3), Jordan (3) — counting where the parties are based and the markets the deals cover.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)